nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—multiple sclerosis	0.242	1	CbGaD
Fluoxetine—CYP2D6—Fingolimod—multiple sclerosis	0.0431	0.1	CbGbCtD
Fluoxetine—ALB—Prednisone—multiple sclerosis	0.0341	0.0794	CbGbCtD
Fluoxetine—ABCB1—Methylprednisolone—multiple sclerosis	0.0295	0.0686	CbGbCtD
Fluoxetine—CYP3A4—Fingolimod—multiple sclerosis	0.0274	0.0638	CbGbCtD
Fluoxetine—CYP2C19—Prednisone—multiple sclerosis	0.0221	0.0515	CbGbCtD
Fluoxetine—CYP2B6—Dexamethasone—multiple sclerosis	0.0217	0.0506	CbGbCtD
Fluoxetine—ABCB1—Mitoxantrone—multiple sclerosis	0.0215	0.05	CbGbCtD
Fluoxetine—ABCB1—Betamethasone—multiple sclerosis	0.0192	0.0446	CbGbCtD
Fluoxetine—ABCB1—Prednisolone—multiple sclerosis	0.0189	0.044	CbGbCtD
Fluoxetine—ABCB1—Prednisone—multiple sclerosis	0.0179	0.0416	CbGbCtD
Fluoxetine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0177	0.0411	CbGbCtD
Fluoxetine—CYP3A5—Dexamethasone—multiple sclerosis	0.0171	0.0399	CbGbCtD
Fluoxetine—ALB—Methotrexate—multiple sclerosis	0.0171	0.0399	CbGbCtD
Fluoxetine—CYP2C19—Dexamethasone—multiple sclerosis	0.0138	0.0322	CbGbCtD
Fluoxetine—CYP3A4—Triamcinolone—multiple sclerosis	0.0134	0.0311	CbGbCtD
Fluoxetine—HTR2A—trigeminal nucleus—multiple sclerosis	0.0129	0.262	CbGeAlD
Fluoxetine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0129	0.03	CbGbCtD
Fluoxetine—CYP2C9—Dexamethasone—multiple sclerosis	0.0115	0.0267	CbGbCtD
Fluoxetine—CYP3A4—Betamethasone—multiple sclerosis	0.0115	0.0267	CbGbCtD
Fluoxetine—CYP3A4—Prednisolone—multiple sclerosis	0.0113	0.0264	CbGbCtD
Fluoxetine—ABCB1—Dexamethasone—multiple sclerosis	0.0111	0.0259	CbGbCtD
Fluoxetine—CYP3A4—Prednisone—multiple sclerosis	0.0107	0.0249	CbGbCtD
Fluoxetine—CYP2D6—Dexamethasone—multiple sclerosis	0.0105	0.0244	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—multiple sclerosis	0.00896	0.0208	CbGbCtD
Fluoxetine—CYP3A4—Dexamethasone—multiple sclerosis	0.00668	0.0155	CbGbCtD
Fluoxetine—HTR2A—trigeminal nerve—multiple sclerosis	0.00339	0.0689	CbGeAlD
Fluoxetine—HTR2A—pons—multiple sclerosis	0.00239	0.0485	CbGeAlD
Fluoxetine—SLC6A2—nerve—multiple sclerosis	0.00206	0.0418	CbGeAlD
Fluoxetine—HTR2A—pineal body—multiple sclerosis	0.0017	0.0346	CbGeAlD
Fluoxetine—HTR2A—peripheral nervous system—multiple sclerosis	0.00159	0.0323	CbGeAlD
Fluoxetine—HTR2A—nerve—multiple sclerosis	0.00124	0.0251	CbGeAlD
Fluoxetine—HTR2C—brainstem—multiple sclerosis	0.00106	0.0215	CbGeAlD
Fluoxetine—SLC6A4—brainstem—multiple sclerosis	0.001	0.0204	CbGeAlD
Fluoxetine—SLC6A2—brainstem—multiple sclerosis	0.000884	0.018	CbGeAlD
Fluoxetine—HTR2C—medulla oblongata—multiple sclerosis	0.000738	0.015	CbGeAlD
Fluoxetine—ORM1—spinal cord—multiple sclerosis	0.000732	0.0149	CbGeAlD
Fluoxetine—SIGMAR1—medulla oblongata—multiple sclerosis	0.000695	0.0141	CbGeAlD
Fluoxetine—HTR2C—midbrain—multiple sclerosis	0.000675	0.0137	CbGeAlD
Fluoxetine—HTR2C—spinal cord—multiple sclerosis	0.000658	0.0134	CbGeAlD
Fluoxetine—SLC6A4—midbrain—multiple sclerosis	0.00064	0.013	CbGeAlD
Fluoxetine—SIGMAR1—midbrain—multiple sclerosis	0.000635	0.0129	CbGeAlD
Fluoxetine—SLC6A4—spinal cord—multiple sclerosis	0.000624	0.0127	CbGeAlD
Fluoxetine—SIGMAR1—spinal cord—multiple sclerosis	0.00062	0.0126	CbGeAlD
Fluoxetine—ORM1—nervous system—multiple sclerosis	0.000617	0.0125	CbGeAlD
Fluoxetine—SLC6A2—medulla oblongata—multiple sclerosis	0.000616	0.0125	CbGeAlD
Fluoxetine—ORM1—central nervous system—multiple sclerosis	0.000594	0.0121	CbGeAlD
Fluoxetine—HTR2C—nervous system—multiple sclerosis	0.000555	0.0113	CbGeAlD
Fluoxetine—HTR2C—central nervous system—multiple sclerosis	0.000534	0.0109	CbGeAlD
Fluoxetine—HTR2A—brainstem—multiple sclerosis	0.000531	0.0108	CbGeAlD
Fluoxetine—SLC6A4—nervous system—multiple sclerosis	0.000526	0.0107	CbGeAlD
Fluoxetine—HTR2A—retina—multiple sclerosis	0.000512	0.0104	CbGeAlD
Fluoxetine—SLC6A4—central nervous system—multiple sclerosis	0.000506	0.0103	CbGeAlD
Fluoxetine—SIGMAR1—cerebellum—multiple sclerosis	0.000491	0.00999	CbGeAlD
Fluoxetine—CYP2D6—brainstem—multiple sclerosis	0.000484	0.00983	CbGeAlD
Fluoxetine—SLC6A2—nervous system—multiple sclerosis	0.000463	0.00941	CbGeAlD
Fluoxetine—SLC6A2—central nervous system—multiple sclerosis	0.000446	0.00906	CbGeAlD
Fluoxetine—HTR2C—brain—multiple sclerosis	0.000424	0.00862	CbGeAlD
Fluoxetine—ALB—brain—multiple sclerosis	0.000414	0.00841	CbGeAlD
Fluoxetine—SLC6A4—brain—multiple sclerosis	0.000402	0.00817	CbGeAlD
Fluoxetine—SIGMAR1—brain—multiple sclerosis	0.000399	0.00811	CbGeAlD
Fluoxetine—HTR2A—medulla oblongata—multiple sclerosis	0.00037	0.00753	CbGeAlD
Fluoxetine—SLC6A2—brain—multiple sclerosis	0.000354	0.00719	CbGeAlD
Fluoxetine—CYP2B6—nervous system—multiple sclerosis	0.000341	0.00693	CbGeAlD
Fluoxetine—HTR2A—midbrain—multiple sclerosis	0.000338	0.00688	CbGeAlD
Fluoxetine—ABCB1—retina—multiple sclerosis	0.000336	0.00682	CbGeAlD
Fluoxetine—HTR2A—spinal cord—multiple sclerosis	0.00033	0.00671	CbGeAlD
Fluoxetine—CYP2B6—central nervous system—multiple sclerosis	0.000328	0.00668	CbGeAlD
Fluoxetine—HTR2A—nervous system—multiple sclerosis	0.000278	0.00566	CbGeAlD
Fluoxetine—HTR2A—central nervous system—multiple sclerosis	0.000268	0.00544	CbGeAlD
Fluoxetine—HTR2A—cerebellum—multiple sclerosis	0.000262	0.00532	CbGeAlD
Fluoxetine—CYP2B6—brain—multiple sclerosis	0.000261	0.0053	CbGeAlD
Fluoxetine—CYP3A4—nervous system—multiple sclerosis	0.000258	0.00524	CbGeAlD
Fluoxetine—CYP2D6—nervous system—multiple sclerosis	0.000253	0.00515	CbGeAlD
Fluoxetine—CYP3A4—central nervous system—multiple sclerosis	0.000248	0.00504	CbGeAlD
Fluoxetine—CYP2D6—central nervous system—multiple sclerosis	0.000244	0.00496	CbGeAlD
Fluoxetine—ABCB1—medulla oblongata—multiple sclerosis	0.000243	0.00493	CbGeAlD
Fluoxetine—CYP2D6—cerebellum—multiple sclerosis	0.000239	0.00485	CbGeAlD
Fluoxetine—ABCB1—midbrain—multiple sclerosis	0.000222	0.00451	CbGeAlD
Fluoxetine—ABCB1—spinal cord—multiple sclerosis	0.000216	0.0044	CbGeAlD
Fluoxetine—HTR2A—brain—multiple sclerosis	0.000213	0.00432	CbGeAlD
Fluoxetine—CYP2D6—brain—multiple sclerosis	0.000194	0.00394	CbGeAlD
Fluoxetine—ABCB1—nervous system—multiple sclerosis	0.000182	0.00371	CbGeAlD
Fluoxetine—ABCB1—central nervous system—multiple sclerosis	0.000176	0.00357	CbGeAlD
Fluoxetine—ABCB1—cerebellum—multiple sclerosis	0.000172	0.00349	CbGeAlD
Fluoxetine—ABCB1—brain—multiple sclerosis	0.000139	0.00283	CbGeAlD
Fluoxetine—Syncope—Dexamethasone—multiple sclerosis	9.23e-05	0.000383	CcSEcCtD
Fluoxetine—Arrhythmia—Prednisone—multiple sclerosis	9.2e-05	0.000382	CcSEcCtD
Fluoxetine—Infection—Triamcinolone—multiple sclerosis	9.19e-05	0.000382	CcSEcCtD
Fluoxetine—Sweating—Methotrexate—multiple sclerosis	9.19e-05	0.000381	CcSEcCtD
Fluoxetine—Infection—Methylprednisolone—multiple sclerosis	9.17e-05	0.000381	CcSEcCtD
Fluoxetine—Haematuria—Methotrexate—multiple sclerosis	9.14e-05	0.000379	CcSEcCtD
Fluoxetine—Shock—Triamcinolone—multiple sclerosis	9.11e-05	0.000378	CcSEcCtD
Fluoxetine—Insomnia—Prednisolone—multiple sclerosis	9.1e-05	0.000378	CcSEcCtD
Fluoxetine—Alopecia—Prednisone—multiple sclerosis	9.1e-05	0.000377	CcSEcCtD
Fluoxetine—Shock—Methylprednisolone—multiple sclerosis	9.09e-05	0.000377	CcSEcCtD
Fluoxetine—Loss of consciousness—Betamethasone—multiple sclerosis	9.04e-05	0.000375	CcSEcCtD
Fluoxetine—Loss of consciousness—Dexamethasone—multiple sclerosis	9.04e-05	0.000375	CcSEcCtD
Fluoxetine—Epistaxis—Methotrexate—multiple sclerosis	9.04e-05	0.000375	CcSEcCtD
Fluoxetine—Hypersensitivity—Mitoxantrone—multiple sclerosis	9.04e-05	0.000375	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisolone—multiple sclerosis	9.04e-05	0.000375	CcSEcCtD
Fluoxetine—Tachycardia—Triamcinolone—multiple sclerosis	9.03e-05	0.000375	CcSEcCtD
Fluoxetine—Mental disorder—Prednisone—multiple sclerosis	9.02e-05	0.000374	CcSEcCtD
Fluoxetine—Nausea—Azathioprine—multiple sclerosis	9.01e-05	0.000374	CcSEcCtD
Fluoxetine—Tachycardia—Methylprednisolone—multiple sclerosis	9.01e-05	0.000374	CcSEcCtD
Fluoxetine—Skin disorder—Methylprednisolone—multiple sclerosis	8.97e-05	0.000372	CcSEcCtD
Fluoxetine—Malnutrition—Prednisone—multiple sclerosis	8.96e-05	0.000372	CcSEcCtD
Fluoxetine—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.95e-05	0.000371	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.93e-05	0.00037	CcSEcCtD
Fluoxetine—Convulsion—Betamethasone—multiple sclerosis	8.92e-05	0.00037	CcSEcCtD
Fluoxetine—Convulsion—Dexamethasone—multiple sclerosis	8.92e-05	0.00037	CcSEcCtD
Fluoxetine—Hypertension—Betamethasone—multiple sclerosis	8.88e-05	0.000369	CcSEcCtD
Fluoxetine—Hypertension—Dexamethasone—multiple sclerosis	8.88e-05	0.000369	CcSEcCtD
Fluoxetine—Asthenia—Mitoxantrone—multiple sclerosis	8.8e-05	0.000365	CcSEcCtD
Fluoxetine—Myalgia—Dexamethasone—multiple sclerosis	8.76e-05	0.000364	CcSEcCtD
Fluoxetine—Myalgia—Betamethasone—multiple sclerosis	8.76e-05	0.000364	CcSEcCtD
Fluoxetine—Anxiety—Dexamethasone—multiple sclerosis	8.73e-05	0.000362	CcSEcCtD
Fluoxetine—Anxiety—Betamethasone—multiple sclerosis	8.73e-05	0.000362	CcSEcCtD
Fluoxetine—Discomfort—Betamethasone—multiple sclerosis	8.66e-05	0.000359	CcSEcCtD
Fluoxetine—Discomfort—Dexamethasone—multiple sclerosis	8.66e-05	0.000359	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—multiple sclerosis	8.65e-05	0.000359	CcSEcCtD
Fluoxetine—Hypotension—Methylprednisolone—multiple sclerosis	8.63e-05	0.000358	CcSEcCtD
Fluoxetine—Pain—Prednisolone—multiple sclerosis	8.61e-05	0.000357	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—multiple sclerosis	8.6e-05	0.000357	CcSEcCtD
Fluoxetine—Haemorrhage—Methotrexate—multiple sclerosis	8.6e-05	0.000357	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—multiple sclerosis	8.54e-05	0.000354	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	8.43e-05	0.00035	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	8.41e-05	0.000349	CcSEcCtD
Fluoxetine—Anaphylactic shock—Betamethasone—multiple sclerosis	8.4e-05	0.000348	CcSEcCtD
Fluoxetine—Anaphylactic shock—Dexamethasone—multiple sclerosis	8.4e-05	0.000348	CcSEcCtD
Fluoxetine—Diarrhoea—Mitoxantrone—multiple sclerosis	8.39e-05	0.000348	CcSEcCtD
Fluoxetine—Insomnia—Triamcinolone—multiple sclerosis	8.37e-05	0.000347	CcSEcCtD
Fluoxetine—Insomnia—Methylprednisolone—multiple sclerosis	8.35e-05	0.000347	CcSEcCtD
Fluoxetine—Infection—Dexamethasone—multiple sclerosis	8.34e-05	0.000346	CcSEcCtD
Fluoxetine—Infection—Betamethasone—multiple sclerosis	8.34e-05	0.000346	CcSEcCtD
Fluoxetine—Ill-defined disorder—Prednisone—multiple sclerosis	8.31e-05	0.000345	CcSEcCtD
Fluoxetine—Paraesthesia—Triamcinolone—multiple sclerosis	8.31e-05	0.000345	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisolone—multiple sclerosis	8.29e-05	0.000344	CcSEcCtD
Fluoxetine—Paraesthesia—Methylprednisolone—multiple sclerosis	8.29e-05	0.000344	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—multiple sclerosis	8.29e-05	0.000344	CcSEcCtD
Fluoxetine—Anaemia—Prednisone—multiple sclerosis	8.28e-05	0.000344	CcSEcCtD
Fluoxetine—Shock—Dexamethasone—multiple sclerosis	8.26e-05	0.000343	CcSEcCtD
Fluoxetine—Shock—Betamethasone—multiple sclerosis	8.26e-05	0.000343	CcSEcCtD
Fluoxetine—Dyspnoea—Triamcinolone—multiple sclerosis	8.25e-05	0.000342	CcSEcCtD
Fluoxetine—Agitation—Prednisone—multiple sclerosis	8.23e-05	0.000342	CcSEcCtD
Fluoxetine—Thrombocytopenia—Betamethasone—multiple sclerosis	8.22e-05	0.000341	CcSEcCtD
Fluoxetine—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.22e-05	0.000341	CcSEcCtD
Fluoxetine—Tachycardia—Betamethasone—multiple sclerosis	8.2e-05	0.00034	CcSEcCtD
Fluoxetine—Tachycardia—Dexamethasone—multiple sclerosis	8.2e-05	0.00034	CcSEcCtD
Fluoxetine—Angioedema—Prednisone—multiple sclerosis	8.19e-05	0.00034	CcSEcCtD
Fluoxetine—Dyspepsia—Triamcinolone—multiple sclerosis	8.15e-05	0.000338	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—multiple sclerosis	8.13e-05	0.000338	CcSEcCtD
Fluoxetine—Dyspepsia—Methylprednisolone—multiple sclerosis	8.13e-05	0.000337	CcSEcCtD
Fluoxetine—Hyperhidrosis—Dexamethasone—multiple sclerosis	8.12e-05	0.000337	CcSEcCtD
Fluoxetine—Hyperhidrosis—Betamethasone—multiple sclerosis	8.12e-05	0.000337	CcSEcCtD
Fluoxetine—Malaise—Prednisone—multiple sclerosis	8.08e-05	0.000335	CcSEcCtD
Fluoxetine—Vertigo—Prednisone—multiple sclerosis	8.05e-05	0.000334	CcSEcCtD
Fluoxetine—Syncope—Prednisone—multiple sclerosis	8.04e-05	0.000333	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—multiple sclerosis	8.02e-05	0.000333	CcSEcCtD
Fluoxetine—Anorexia—Dexamethasone—multiple sclerosis	8e-05	0.000332	CcSEcCtD
Fluoxetine—Anorexia—Betamethasone—multiple sclerosis	8e-05	0.000332	CcSEcCtD
Fluoxetine—Urticaria—Prednisolone—multiple sclerosis	8e-05	0.000332	CcSEcCtD
Fluoxetine—Fatigue—Triamcinolone—multiple sclerosis	7.98e-05	0.000331	CcSEcCtD
Fluoxetine—Fatigue—Methylprednisolone—multiple sclerosis	7.96e-05	0.00033	CcSEcCtD
Fluoxetine—Pain—Triamcinolone—multiple sclerosis	7.91e-05	0.000328	CcSEcCtD
Fluoxetine—Loss of consciousness—Prednisone—multiple sclerosis	7.88e-05	0.000327	CcSEcCtD
Fluoxetine—Hypotension—Betamethasone—multiple sclerosis	7.85e-05	0.000326	CcSEcCtD
Fluoxetine—Hypotension—Dexamethasone—multiple sclerosis	7.85e-05	0.000326	CcSEcCtD
Fluoxetine—Vomiting—Mitoxantrone—multiple sclerosis	7.8e-05	0.000324	CcSEcCtD
Fluoxetine—Convulsion—Prednisone—multiple sclerosis	7.76e-05	0.000322	CcSEcCtD
Fluoxetine—Hypertension—Prednisone—multiple sclerosis	7.74e-05	0.000321	CcSEcCtD
Fluoxetine—Rash—Mitoxantrone—multiple sclerosis	7.73e-05	0.000321	CcSEcCtD
Fluoxetine—Dermatitis—Mitoxantrone—multiple sclerosis	7.73e-05	0.000321	CcSEcCtD
Fluoxetine—Chills—Methotrexate—multiple sclerosis	7.72e-05	0.00032	CcSEcCtD
Fluoxetine—Headache—Mitoxantrone—multiple sclerosis	7.69e-05	0.000319	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.65e-05	0.000317	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.65e-05	0.000317	CcSEcCtD
Fluoxetine—Myalgia—Prednisone—multiple sclerosis	7.63e-05	0.000317	CcSEcCtD
Fluoxetine—Arthralgia—Prednisone—multiple sclerosis	7.63e-05	0.000317	CcSEcCtD
Fluoxetine—Feeling abnormal—Triamcinolone—multiple sclerosis	7.63e-05	0.000316	CcSEcCtD
Fluoxetine—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.61e-05	0.000316	CcSEcCtD
Fluoxetine—Anxiety—Prednisone—multiple sclerosis	7.6e-05	0.000315	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—multiple sclerosis	7.6e-05	0.000315	CcSEcCtD
Fluoxetine—Insomnia—Betamethasone—multiple sclerosis	7.6e-05	0.000315	CcSEcCtD
Fluoxetine—Insomnia—Dexamethasone—multiple sclerosis	7.6e-05	0.000315	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	7.58e-05	0.000314	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.55e-05	0.000313	CcSEcCtD
Fluoxetine—Paraesthesia—Betamethasone—multiple sclerosis	7.54e-05	0.000313	CcSEcCtD
Fluoxetine—Paraesthesia—Dexamethasone—multiple sclerosis	7.54e-05	0.000313	CcSEcCtD
Fluoxetine—Discomfort—Prednisone—multiple sclerosis	7.54e-05	0.000313	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—multiple sclerosis	7.54e-05	0.000313	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—multiple sclerosis	7.49e-05	0.000311	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisolone—multiple sclerosis	7.41e-05	0.000308	CcSEcCtD
Fluoxetine—Dyspepsia—Dexamethasone—multiple sclerosis	7.39e-05	0.000307	CcSEcCtD
Fluoxetine—Dyspepsia—Betamethasone—multiple sclerosis	7.39e-05	0.000307	CcSEcCtD
Fluoxetine—Urticaria—Triamcinolone—multiple sclerosis	7.35e-05	0.000305	CcSEcCtD
Fluoxetine—Urticaria—Methylprednisolone—multiple sclerosis	7.34e-05	0.000304	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—multiple sclerosis	7.33e-05	0.000304	CcSEcCtD
Fluoxetine—Body temperature increased—Triamcinolone—multiple sclerosis	7.32e-05	0.000304	CcSEcCtD
Fluoxetine—Anaphylactic shock—Prednisone—multiple sclerosis	7.31e-05	0.000303	CcSEcCtD
Fluoxetine—Abdominal pain—Methylprednisolone—multiple sclerosis	7.3e-05	0.000303	CcSEcCtD
Fluoxetine—Decreased appetite—Betamethasone—multiple sclerosis	7.3e-05	0.000303	CcSEcCtD
Fluoxetine—Decreased appetite—Dexamethasone—multiple sclerosis	7.3e-05	0.000303	CcSEcCtD
Fluoxetine—Nausea—Mitoxantrone—multiple sclerosis	7.29e-05	0.000302	CcSEcCtD
Fluoxetine—Infection—Prednisone—multiple sclerosis	7.27e-05	0.000301	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.25e-05	0.000301	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.25e-05	0.000301	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—multiple sclerosis	7.24e-05	0.000301	CcSEcCtD
Fluoxetine—Fatigue—Dexamethasone—multiple sclerosis	7.24e-05	0.0003	CcSEcCtD
Fluoxetine—Fatigue—Betamethasone—multiple sclerosis	7.24e-05	0.0003	CcSEcCtD
Fluoxetine—Shock—Prednisone—multiple sclerosis	7.2e-05	0.000299	CcSEcCtD
Fluoxetine—Pain—Dexamethasone—multiple sclerosis	7.18e-05	0.000298	CcSEcCtD
Fluoxetine—Pain—Betamethasone—multiple sclerosis	7.18e-05	0.000298	CcSEcCtD
Fluoxetine—Tachycardia—Prednisone—multiple sclerosis	7.14e-05	0.000296	CcSEcCtD
Fluoxetine—Skin disorder—Prednisone—multiple sclerosis	7.1e-05	0.000295	CcSEcCtD
Fluoxetine—Hyperhidrosis—Prednisone—multiple sclerosis	7.07e-05	0.000293	CcSEcCtD
Fluoxetine—Anorexia—Prednisone—multiple sclerosis	6.97e-05	0.000289	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—multiple sclerosis	6.95e-05	0.000288	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—multiple sclerosis	6.92e-05	0.000287	CcSEcCtD
Fluoxetine—Feeling abnormal—Betamethasone—multiple sclerosis	6.92e-05	0.000287	CcSEcCtD
Fluoxetine—Feeling abnormal—Dexamethasone—multiple sclerosis	6.92e-05	0.000287	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.87e-05	0.000285	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.87e-05	0.000285	CcSEcCtD
Fluoxetine—Hypersensitivity—Triamcinolone—multiple sclerosis	6.82e-05	0.000283	CcSEcCtD
Fluoxetine—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.8e-05	0.000282	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—multiple sclerosis	6.75e-05	0.00028	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—multiple sclerosis	6.73e-05	0.000279	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—multiple sclerosis	6.7e-05	0.000278	CcSEcCtD
Fluoxetine—Urticaria—Betamethasone—multiple sclerosis	6.67e-05	0.000277	CcSEcCtD
Fluoxetine—Urticaria—Dexamethasone—multiple sclerosis	6.67e-05	0.000277	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.66e-05	0.000276	CcSEcCtD
Fluoxetine—Dizziness—Prednisolone—multiple sclerosis	6.66e-05	0.000276	CcSEcCtD
Fluoxetine—Asthenia—Triamcinolone—multiple sclerosis	6.64e-05	0.000276	CcSEcCtD
Fluoxetine—Body temperature increased—Dexamethasone—multiple sclerosis	6.64e-05	0.000275	CcSEcCtD
Fluoxetine—Body temperature increased—Betamethasone—multiple sclerosis	6.64e-05	0.000275	CcSEcCtD
Fluoxetine—Abdominal pain—Dexamethasone—multiple sclerosis	6.64e-05	0.000275	CcSEcCtD
Fluoxetine—Abdominal pain—Betamethasone—multiple sclerosis	6.64e-05	0.000275	CcSEcCtD
Fluoxetine—Asthenia—Methylprednisolone—multiple sclerosis	6.63e-05	0.000275	CcSEcCtD
Fluoxetine—Insomnia—Prednisone—multiple sclerosis	6.61e-05	0.000274	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisone—multiple sclerosis	6.57e-05	0.000272	CcSEcCtD
Fluoxetine—Pruritus—Triamcinolone—multiple sclerosis	6.55e-05	0.000272	CcSEcCtD
Fluoxetine—Cough—Methotrexate—multiple sclerosis	6.54e-05	0.000271	CcSEcCtD
Fluoxetine—Pruritus—Methylprednisolone—multiple sclerosis	6.53e-05	0.000271	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—multiple sclerosis	6.49e-05	0.000269	CcSEcCtD
Fluoxetine—Dyspepsia—Prednisone—multiple sclerosis	6.44e-05	0.000267	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—multiple sclerosis	6.38e-05	0.000265	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—multiple sclerosis	6.38e-05	0.000265	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—multiple sclerosis	6.38e-05	0.000265	CcSEcCtD
Fluoxetine—Decreased appetite—Prednisone—multiple sclerosis	6.36e-05	0.000264	CcSEcCtD
Fluoxetine—Rash—Prednisolone—multiple sclerosis	6.35e-05	0.000263	CcSEcCtD
Fluoxetine—Dermatitis—Prednisolone—multiple sclerosis	6.34e-05	0.000263	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.33e-05	0.000263	CcSEcCtD
Fluoxetine—Diarrhoea—Methylprednisolone—multiple sclerosis	6.32e-05	0.000262	CcSEcCtD
Fluoxetine—Fatigue—Prednisone—multiple sclerosis	6.31e-05	0.000262	CcSEcCtD
Fluoxetine—Headache—Prednisolone—multiple sclerosis	6.3e-05	0.000262	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—multiple sclerosis	6.3e-05	0.000261	CcSEcCtD
Fluoxetine—Constipation—Prednisone—multiple sclerosis	6.25e-05	0.00026	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—multiple sclerosis	6.16e-05	0.000256	CcSEcCtD
Fluoxetine—Dizziness—Triamcinolone—multiple sclerosis	6.12e-05	0.000254	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—multiple sclerosis	6.11e-05	0.000254	CcSEcCtD
Fluoxetine—Dizziness—Methylprednisolone—multiple sclerosis	6.11e-05	0.000253	CcSEcCtD
Fluoxetine—Infection—Methotrexate—multiple sclerosis	6.07e-05	0.000252	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisone—multiple sclerosis	6.03e-05	0.00025	CcSEcCtD
Fluoxetine—Asthenia—Betamethasone—multiple sclerosis	6.03e-05	0.00025	CcSEcCtD
Fluoxetine—Asthenia—Dexamethasone—multiple sclerosis	6.03e-05	0.00025	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—multiple sclerosis	5.98e-05	0.000248	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Prednisone—multiple sclerosis	5.98e-05	0.000248	CcSEcCtD
Fluoxetine—Nausea—Prednisolone—multiple sclerosis	5.98e-05	0.000248	CcSEcCtD
Fluoxetine—Pruritus—Dexamethasone—multiple sclerosis	5.94e-05	0.000247	CcSEcCtD
Fluoxetine—Pruritus—Betamethasone—multiple sclerosis	5.94e-05	0.000247	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—multiple sclerosis	5.94e-05	0.000246	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—multiple sclerosis	5.91e-05	0.000245	CcSEcCtD
Fluoxetine—Vomiting—Triamcinolone—multiple sclerosis	5.88e-05	0.000244	CcSEcCtD
Fluoxetine—Vomiting—Methylprednisolone—multiple sclerosis	5.87e-05	0.000244	CcSEcCtD
Fluoxetine—Rash—Triamcinolone—multiple sclerosis	5.84e-05	0.000242	CcSEcCtD
Fluoxetine—Dermatitis—Triamcinolone—multiple sclerosis	5.83e-05	0.000242	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—multiple sclerosis	5.83e-05	0.000242	CcSEcCtD
Fluoxetine—Rash—Methylprednisolone—multiple sclerosis	5.82e-05	0.000242	CcSEcCtD
Fluoxetine—Dermatitis—Methylprednisolone—multiple sclerosis	5.82e-05	0.000241	CcSEcCtD
Fluoxetine—Urticaria—Prednisone—multiple sclerosis	5.81e-05	0.000241	CcSEcCtD
Fluoxetine—Headache—Triamcinolone—multiple sclerosis	5.8e-05	0.000241	CcSEcCtD
Fluoxetine—Headache—Methylprednisolone—multiple sclerosis	5.79e-05	0.00024	CcSEcCtD
Fluoxetine—Abdominal pain—Prednisone—multiple sclerosis	5.78e-05	0.00024	CcSEcCtD
Fluoxetine—Body temperature increased—Prednisone—multiple sclerosis	5.78e-05	0.00024	CcSEcCtD
Fluoxetine—Diarrhoea—Betamethasone—multiple sclerosis	5.75e-05	0.000238	CcSEcCtD
Fluoxetine—Diarrhoea—Dexamethasone—multiple sclerosis	5.75e-05	0.000238	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—multiple sclerosis	5.71e-05	0.000237	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.57e-05	0.000231	CcSEcCtD
Fluoxetine—Dizziness—Dexamethasone—multiple sclerosis	5.55e-05	0.00023	CcSEcCtD
Fluoxetine—Dizziness—Betamethasone—multiple sclerosis	5.55e-05	0.00023	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—multiple sclerosis	5.53e-05	0.000229	CcSEcCtD
Fluoxetine—Nausea—Triamcinolone—multiple sclerosis	5.5e-05	0.000228	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—multiple sclerosis	5.49e-05	0.000228	CcSEcCtD
Fluoxetine—Nausea—Methylprednisolone—multiple sclerosis	5.49e-05	0.000228	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—multiple sclerosis	5.45e-05	0.000226	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—multiple sclerosis	5.43e-05	0.000225	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisone—multiple sclerosis	5.39e-05	0.000224	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—multiple sclerosis	5.38e-05	0.000223	CcSEcCtD
Fluoxetine—Vomiting—Dexamethasone—multiple sclerosis	5.34e-05	0.000222	CcSEcCtD
Fluoxetine—Vomiting—Betamethasone—multiple sclerosis	5.34e-05	0.000222	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—multiple sclerosis	5.31e-05	0.00022	CcSEcCtD
Fluoxetine—Rash—Betamethasone—multiple sclerosis	5.29e-05	0.00022	CcSEcCtD
Fluoxetine—Rash—Dexamethasone—multiple sclerosis	5.29e-05	0.00022	CcSEcCtD
Fluoxetine—Dermatitis—Dexamethasone—multiple sclerosis	5.29e-05	0.00022	CcSEcCtD
Fluoxetine—Dermatitis—Betamethasone—multiple sclerosis	5.29e-05	0.00022	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.28e-05	0.000219	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—multiple sclerosis	5.27e-05	0.000219	CcSEcCtD
Fluoxetine—Headache—Betamethasone—multiple sclerosis	5.26e-05	0.000218	CcSEcCtD
Fluoxetine—Headache—Dexamethasone—multiple sclerosis	5.26e-05	0.000218	CcSEcCtD
Fluoxetine—Asthenia—Prednisone—multiple sclerosis	5.25e-05	0.000218	CcSEcCtD
Fluoxetine—Pain—Methotrexate—multiple sclerosis	5.23e-05	0.000217	CcSEcCtD
Fluoxetine—Pruritus—Prednisone—multiple sclerosis	5.17e-05	0.000215	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—multiple sclerosis	5.04e-05	0.000209	CcSEcCtD
Fluoxetine—Diarrhoea—Prednisone—multiple sclerosis	5e-05	0.000208	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—multiple sclerosis	5e-05	0.000207	CcSEcCtD
Fluoxetine—Nausea—Dexamethasone—multiple sclerosis	4.99e-05	0.000207	CcSEcCtD
Fluoxetine—Nausea—Betamethasone—multiple sclerosis	4.99e-05	0.000207	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—multiple sclerosis	4.86e-05	0.000201	CcSEcCtD
Fluoxetine—Dizziness—Prednisone—multiple sclerosis	4.84e-05	0.000201	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—multiple sclerosis	4.83e-05	0.0002	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—multiple sclerosis	4.83e-05	0.0002	CcSEcCtD
Fluoxetine—Vomiting—Prednisone—multiple sclerosis	4.65e-05	0.000193	CcSEcCtD
Fluoxetine—Rash—Prednisone—multiple sclerosis	4.61e-05	0.000191	CcSEcCtD
Fluoxetine—Dermatitis—Prednisone—multiple sclerosis	4.61e-05	0.000191	CcSEcCtD
Fluoxetine—Headache—Prednisone—multiple sclerosis	4.58e-05	0.00019	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—multiple sclerosis	4.5e-05	0.000187	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—multiple sclerosis	4.39e-05	0.000182	CcSEcCtD
Fluoxetine—Nausea—Prednisone—multiple sclerosis	4.34e-05	0.00018	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—multiple sclerosis	4.32e-05	0.000179	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—multiple sclerosis	4.18e-05	0.000174	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—multiple sclerosis	4.04e-05	0.000168	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—multiple sclerosis	3.89e-05	0.000161	CcSEcCtD
Fluoxetine—Rash—Methotrexate—multiple sclerosis	3.85e-05	0.00016	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—multiple sclerosis	3.85e-05	0.00016	CcSEcCtD
Fluoxetine—Headache—Methotrexate—multiple sclerosis	3.83e-05	0.000159	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—multiple sclerosis	3.63e-05	0.000151	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.59e-05	0.000676	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SRM—multiple sclerosis	2.58e-05	0.000674	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CCR5—multiple sclerosis	2.58e-05	0.000674	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—S1PR1—multiple sclerosis	2.56e-05	0.000667	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TAGAP—multiple sclerosis	2.54e-05	0.000663	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SRM—multiple sclerosis	2.52e-05	0.000658	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	2.51e-05	0.000655	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—IL6—multiple sclerosis	2.49e-05	0.000651	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CCL5—multiple sclerosis	2.49e-05	0.000649	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GPC5—multiple sclerosis	2.49e-05	0.000649	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.47e-05	0.000643	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	2.45e-05	0.000641	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.44e-05	0.000638	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PTGER4—multiple sclerosis	2.41e-05	0.000629	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	2.41e-05	0.000628	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	2.41e-05	0.000628	CbGpPWpGaD
Fluoxetine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	2.39e-05	0.000625	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SRM—multiple sclerosis	2.38e-05	0.00062	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—IL6—multiple sclerosis	2.37e-05	0.000618	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SRM—multiple sclerosis	2.35e-05	0.000615	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.35e-05	0.000614	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.35e-05	0.000614	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.34e-05	0.000612	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCR3—multiple sclerosis	2.33e-05	0.000607	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.3e-05	0.0006	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCL3—multiple sclerosis	2.27e-05	0.000593	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CCR2—multiple sclerosis	2.26e-05	0.000591	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.25e-05	0.000587	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CCR5—multiple sclerosis	2.24e-05	0.000585	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—S1PR1—multiple sclerosis	2.22e-05	0.000579	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.2e-05	0.000575	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.2e-05	0.000575	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PTGER4—multiple sclerosis	2.19e-05	0.000571	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.18e-05	0.00057	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RGS1—multiple sclerosis	2.17e-05	0.000567	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	2.16e-05	0.000564	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.16e-05	0.000564	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GPC5—multiple sclerosis	2.16e-05	0.000563	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.15e-05	0.000562	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCR3—multiple sclerosis	2.11e-05	0.000551	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PTGER4—multiple sclerosis	2.09e-05	0.000546	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CNR1—multiple sclerosis	2.09e-05	0.000545	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—ITGA4—multiple sclerosis	2.08e-05	0.000542	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IFNB1—multiple sclerosis	2.06e-05	0.000538	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GPR65—multiple sclerosis	2.06e-05	0.000538	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCR2—multiple sclerosis	2.06e-05	0.000536	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP27B1—multiple sclerosis	2.03e-05	0.000529	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP24A1—multiple sclerosis	2.03e-05	0.000529	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	2.02e-05	0.000528	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCR3—multiple sclerosis	2.02e-05	0.000527	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—POMC—multiple sclerosis	2.02e-05	0.000526	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SRM—multiple sclerosis	2.01e-05	0.000525	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.98e-05	0.000517	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	1.98e-05	0.000517	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CCL2—multiple sclerosis	1.97e-05	0.000515	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCL3—multiple sclerosis	1.97e-05	0.000515	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CCR2—multiple sclerosis	1.97e-05	0.000513	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PTGER4—multiple sclerosis	1.9e-05	0.000496	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CNR1—multiple sclerosis	1.9e-05	0.000495	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RGS1—multiple sclerosis	1.89e-05	0.000493	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL13—multiple sclerosis	1.88e-05	0.000492	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCR1—multiple sclerosis	1.88e-05	0.000492	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCL10—multiple sclerosis	1.88e-05	0.000491	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.86e-05	0.000487	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GPC5—multiple sclerosis	1.85e-05	0.000484	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCR3—multiple sclerosis	1.83e-05	0.000479	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—RRM1—multiple sclerosis	1.82e-05	0.000476	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	1.82e-05	0.000475	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	1.82e-05	0.000475	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CNR1—multiple sclerosis	1.81e-05	0.000473	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GPR65—multiple sclerosis	1.79e-05	0.000467	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCR2—multiple sclerosis	1.78e-05	0.000466	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.78e-05	0.000466	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.78e-05	0.000464	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.000464	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.000464	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.77e-05	0.000461	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.76e-05	0.000458	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—POMC—multiple sclerosis	1.75e-05	0.000457	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	1.74e-05	0.000455	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CCL2—multiple sclerosis	1.71e-05	0.000447	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL10—multiple sclerosis	1.71e-05	0.000446	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.67e-05	0.000437	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.67e-05	0.000437	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GPC5—multiple sclerosis	1.66e-05	0.000434	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.66e-05	0.000433	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.66e-05	0.000433	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CNR1—multiple sclerosis	1.65e-05	0.00043	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL13—multiple sclerosis	1.64e-05	0.000427	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCR1—multiple sclerosis	1.64e-05	0.000427	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL10—multiple sclerosis	1.63e-05	0.000426	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GPC5—multiple sclerosis	1.62e-05	0.000424	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.62e-05	0.000423	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CCL5—multiple sclerosis	1.62e-05	0.000423	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	1.61e-05	0.000421	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.55e-05	0.000406	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.55e-05	0.000405	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—RRM1—multiple sclerosis	1.54e-05	0.000401	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.53e-05	0.000399	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.52e-05	0.000396	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL10—multiple sclerosis	1.48e-05	0.000387	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCL5—multiple sclerosis	1.47e-05	0.000384	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CCR5—multiple sclerosis	1.46e-05	0.000381	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.44e-05	0.000376	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2RA—multiple sclerosis	1.44e-05	0.000375	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2RA—multiple sclerosis	1.42e-05	0.00037	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.42e-05	0.00037	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.42e-05	0.00037	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CCL5—multiple sclerosis	1.41e-05	0.000367	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.39e-05	0.000362	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.38e-05	0.00036	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.35e-05	0.000352	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000351	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL3—multiple sclerosis	1.34e-05	0.00035	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCR5—multiple sclerosis	1.32e-05	0.000346	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2RA—multiple sclerosis	1.31e-05	0.000341	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.3e-05	0.000338	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTGER4—multiple sclerosis	1.29e-05	0.000337	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	1.28e-05	0.000333	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PGR—multiple sclerosis	1.27e-05	0.000332	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.27e-05	0.000331	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	1.27e-05	0.000331	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.26e-05	0.000328	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.26e-05	0.000328	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	1.25e-05	0.000326	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCR3—multiple sclerosis	1.25e-05	0.000326	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.24e-05	0.000324	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.24e-05	0.000323	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CD28—multiple sclerosis	1.24e-05	0.000323	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.23e-05	0.000322	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.21e-05	0.000317	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCR2—multiple sclerosis	1.21e-05	0.000317	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.19e-05	0.000311	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	1.17e-05	0.000304	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.16e-05	0.000302	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	1.15e-05	0.0003	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—POMC—multiple sclerosis	1.14e-05	0.000298	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	1.13e-05	0.000296	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	1.12e-05	0.000293	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CNR1—multiple sclerosis	1.12e-05	0.000292	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PGR—multiple sclerosis	1.11e-05	0.000288	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.09e-05	0.000286	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.09e-05	0.000286	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	1.08e-05	0.000283	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.00028	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD28—multiple sclerosis	1.07e-05	0.00028	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.07e-05	0.000279	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	1.05e-05	0.000275	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.05e-05	0.000274	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—POMC—multiple sclerosis	1.04e-05	0.00027	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.02e-05	0.000267	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.02e-05	0.000267	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCL2—multiple sclerosis	1.01e-05	0.000264	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL10—multiple sclerosis	1.01e-05	0.000263	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1e-05	0.000261	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	9.9e-06	0.000258	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.76e-06	0.000255	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	9.73e-06	0.000254	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—TYK2—multiple sclerosis	9.2e-06	0.00024	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.19e-06	0.00024	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	8.99e-06	0.000235	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—BCHE—multiple sclerosis	8.82e-06	0.00023	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CD86—multiple sclerosis	8.82e-06	0.00023	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	8.8e-06	0.00023	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	8.76e-06	0.000229	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	8.68e-06	0.000227	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	8.43e-06	0.00022	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.38e-06	0.000219	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.38e-06	0.000219	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.34e-06	0.000218	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2—multiple sclerosis	8.31e-06	0.000217	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—RRM1—multiple sclerosis	8.29e-06	0.000216	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	8.04e-06	0.00021	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	7.99e-06	0.000208	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—BCHE—multiple sclerosis	7.92e-06	0.000207	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	7.82e-06	0.000204	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.78e-06	0.000203	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—BCHE—multiple sclerosis	7.73e-06	0.000202	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	7.71e-06	0.000201	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD86—multiple sclerosis	7.66e-06	0.0002	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	7.65e-06	0.0002	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.64e-06	0.000199	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	7.54e-06	0.000197	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	7.32e-06	0.000191	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—BCHE—multiple sclerosis	7.28e-06	0.00019	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—BCHE—multiple sclerosis	7.22e-06	0.000188	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.16e-06	0.000187	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOE—multiple sclerosis	7.12e-06	0.000186	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	6.98e-06	0.000182	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	6.79e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	6.7e-06	0.000175	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	6.65e-06	0.000173	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.53e-06	0.00017	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—multiple sclerosis	6.49e-06	0.000169	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CD80—multiple sclerosis	6.44e-06	0.000168	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—multiple sclerosis	6.36e-06	0.000166	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOE—multiple sclerosis	6.31e-06	0.000165	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOE—multiple sclerosis	6.18e-06	0.000161	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—BCHE—multiple sclerosis	6.17e-06	0.000161	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOE—multiple sclerosis	6.16e-06	0.000161	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—POMC—multiple sclerosis	6.11e-06	0.00016	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	5.98e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	5.85e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CD80—multiple sclerosis	5.59e-06	0.000146	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	5.43e-06	0.000142	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—POMC—multiple sclerosis	5.42e-06	0.000141	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—POMC—multiple sclerosis	5.31e-06	0.000139	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOE—multiple sclerosis	5.31e-06	0.000139	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—POMC—multiple sclerosis	5.29e-06	0.000138	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	5.2e-06	0.000136	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	5.08e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—multiple sclerosis	4.94e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—multiple sclerosis	4.83e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOE—multiple sclerosis	4.76e-06	0.000124	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.76e-06	0.000124	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	4.72e-06	0.000123	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOE—multiple sclerosis	4.65e-06	0.000121	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—POMC—multiple sclerosis	4.56e-06	0.000119	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—multiple sclerosis	4.52e-06	0.000118	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	4.5e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOE—multiple sclerosis	4.38e-06	0.000114	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOE—multiple sclerosis	4.34e-06	0.000113	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	4.28e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—POMC—multiple sclerosis	4.09e-06	0.000107	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—POMC—multiple sclerosis	4e-06	0.000104	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—multiple sclerosis	3.93e-06	0.000102	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	3.91e-06	0.000102	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	3.8e-06	9.93e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—POMC—multiple sclerosis	3.76e-06	9.83e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—POMC—multiple sclerosis	3.73e-06	9.74e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—multiple sclerosis	3.73e-06	9.74e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	3.72e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOE—multiple sclerosis	3.71e-06	9.69e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—multiple sclerosis	3.64e-06	9.51e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—multiple sclerosis	3.53e-06	9.23e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	3.53e-06	9.2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	3.46e-06	9.03e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—multiple sclerosis	3.43e-06	8.96e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—multiple sclerosis	3.4e-06	8.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	3.3e-06	8.62e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—POMC—multiple sclerosis	3.19e-06	8.32e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—multiple sclerosis	3.07e-06	8.01e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	3.06e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	3e-06	7.84e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—multiple sclerosis	2.91e-06	7.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.87e-06	7.48e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—multiple sclerosis	2.66e-06	6.93e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—POMC—multiple sclerosis	2.46e-06	6.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—multiple sclerosis	2.31e-06	6.02e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.24e-06	5.86e-05	CbGpPWpGaD
